T echnologies for minimally invasive and remote stimulation of specific neurons deep in the brain have long been desired for the experimental interrogation of neural systems and clinical treatment of neurological disorders. Deep brain stimulation is effective in the alleviation of specific neurological symptoms, but lacks cell-type specificity and requires permanently implanted electrodes (1) . Potential alternatives for brain tissue-penetrating stimuli include electric (2, 3), magnetic (2, 4, 5) , acoustic (6, 7) , and optical signals (8) . These approaches were largely developed independently of the optogenetic toolbox established over the past decade (9) and therefore remain limited to discrete applications. Stimulation of deep brain neurons via light-gated ion channels has hitherto required the insertion of invasive optical fibers because the activating blue-green wavelengths are strongly scattered and absorbed by endogenous chromophores (10) . The action spectra of red-shifted variants of rhodopsins still fall short of the nearinfrared (NIR) optical window (650 to 1350 nm), where light has its maximal depth of penetration (10) (11) (12) (13) (14) (15) . Two-photon optogenetic methods allow in vivo stimulation via an NIR laser, but the depth of this focal excitation is restricted to shallow brain areas by light scattering (16) .
We developed transcranial NIR optogenetic stimulation of specifically labeled neurons in deep brain areas, where tissue-penetrating NIR light is locally converted to visible light at levels sufficient for activating channelrhodopsin-expressing neurons (Fig. 1A) . This requires lanthanide-doped upconversion nanoparticles (UCNPs) capable of converting low-energy incident NIR photons into high-energy visible emission with an efficiency orders of magnitude greater than that of multiphoton processes (Fig. 1 , B to D) (17, 18) . As a result, a continuous-wave (CW) NIR laser diode at low-energy irradiance was sufficient to drive intense upconversion emission by UCNPs. Owing to the ladderlike electronic energy structure of the lanthanide, the emission of UCNPs can be precisely tuned to a particular wavelength by control of energy transfer via selective lanthanideion doping (17, 18) . Incorporation of Tm 3+ into Yb 3+ -doped host lattices leads to blue emission that matches the maximum absorption of channelrhodopsin-2 (ChR2) for neuronal activation, whereas the Yb 3+ -Er 3+ couple emits green light compatible with activation of halorhodopsin (NpHR) or archaerhodopsin (Arch) for neuronal inhibition (Fig. 1, C and D, and figs. S1 and S2). UCNP-mediated optogenetics was first proposed in 2011 (19) and used for neural stimulation in culture (20) (21) (22) and in Caenorhabditis elegans (23) and zebrafish larvae (24), but its compelling potential for minimally invasive deep brain stimulation in a mammalian system has yet to be demonstrated.
We reasoned that UCNP-mediated optogenetics would be feasible for transcranial stimulation of deep brain neurons in rodents based on an evaluation of (i) the efficiency of NIR upconversion by the nanoparticles (Fig. 1D and fig. S3 ) and (ii) the transmittance of NIR light in brain tissue (figs. S4 and S5). For ChR2 activation, we synthesized blue-emitting NaYF 4 nanocrystals codoped with Yb 3+ /Tm 3+ (Fig. 1C ). An optically inert shell layer of NaYF 4 was epitaxially grown onto the core to eliminate the surface quenching of upconversion luminescence by solvent molecules. The resulting core-shell UCNPs exhibited a characteristic upconversion emission spectrum peaking at 450 and 475 nm upon excitation at 980 nm (Fig. 1D) . The conversion yield of NIR to blue light was~2.5% (Fig. 1D and fig. S3 ). Applying the Kubelka-Munk theory of light propagation in diffuse scattering media (25) , we estimated that a 2.0-W 980-nm laser delivered over the mouse skull through an optic fiber (200 mm in diameter) would result in 13.8-mW/mm 2 NIR at a depth of 4.5 mm in the brain. At this intensity, local upconversion by UCNPs would generate 0.34-mW/mm 2 blue-light emission (supplementary text), sufficient to activate ChR2 for cation influx ( fig. S6) .
We therefore performed in vivo fiber photometry (26) to examine NIR upconversion by UCNPs in the ventral tegmental area (VTA) of the mouse brain, a region located~4.2 mm below the skull. UCNPs were injected into the VTA, and an optic fiber was positioned nearby to record blue emission (Fig. 1, F and G) . Upon transcranial delivery of 980-nm CW laser pulses at a peak power of 2.0 W (25-ms pulses at 20 Hz over 1 s), an upconverted emission with a power density of~0.063 mW/mm 2 was detected ( Fig.  1H and fig. S5 ). This value was in line with our estimates based on the Kubelka-Munk theory when an empirical loss term was included (supplementary text). Further, considering that fiber photometry can only partially capture the emitted photons, this value represents a lower bound but nonetheless exceeds the level sufficient for ChR2 activation ( fig. S6 ).
For the stimulation of a specific brain region, the power of transcranial NIR irradiation can be tuned according to its depth. NIR light is largely transparent, and its limited absorption results in minimal increases in local temperature because of constant circulation; thus, NIR pulses delivered across a wide range of laser energies to living tissue result in little photochemical or thermal damage (27, 28) . Nonetheless, at higher powers, it is important to consider a possible heating effect of NIR on the tissue. Our measurements of temperature change in the brain tissue showed that only mild temperature increases were induced under the conditions used in our study (supplementary text, figs. S7 and S8, and table S2). Immunohistochemical assessments further confirmed the absence of cytotoxicity ( fig. S9) . However, before a NIR strategy is adopted, the stimulation parameters should always be optimized for a balance between safety and efficacy. To optimize the biocompatibility and long-term utility of UCNPs, we decorated the core-shell NaYF 4 :Yb/Tm nanocrystals with silica (NaYF 4 : Yb/Tm@SiO2) or poly(acrylic acid) (PAA) (NaYF 4 :
Yb/Tm@PAA). Both coating strategies resulted in monodispersed UCNPs of~90-nm diameter (Fig. 1, B and E, and figs. S1 and S2) with similar luminescence profiles (Fig. 1D and fig. S1 ). One month after injection, UCNPs could still be observed at the target site, regardless of the type of coating (figs. S10 and S11), suggesting their longterm stability and low dispersion in tissue. We selected silica-coated UCNPs for in vivo upconversion optogenetics because they showed minimum cytotoxicity compared to the PAA-grafted ones, as indicated by less glial activation and lower macrophage accumulation in the VTA over prolonged exposure (figs. S10 and S11). This is likely a result of the silica coating that chemically stabilizes the nanoparticles and prevents direct contact of their lanthanide-doped core to cells within the tissue (29) .
We chose the VTA for an initial examination of NIR stimulation because it is a deep brain region with a well-characterized anatomy and function. An adeno-associated virus (AAV) encoding ChR2-EYFP (enhanced yellow fluorescent protein) in a double-floxed inverted open reading frame (DIO) was injected into the VTA of tyrosine hydroxylase (TH)-driven Cre recombinase (TH-Cre) transgenic mice, resulting in Cre-dependent expression of ChR2 in dopamine (DA) neurons ( Fig. 2A) . Four weeks later, 900 nl of 200 mg/ml blue-emitting NaYF 4 :Yb/Tm@SiO 2 UCNPs was injected into the VTA. We first assayed UCNP-mediated optogenetic activation of DA neurons in acute slices. Electron microscopy ( Fig. 2B and fig. S12 ) showed that the UCNPs were localized in the injection area without extensive diffusion. The majority were distributed in extracellular spaces in the vicinity of cell membrane and synaptic clefts. A small fraction of UCNPs were taken up by neurons, mainly localized to axons, as well as by microglia. The confinement of UCNPs in the target brain region agrees with our light microscopy results showing that UCNPs exhibited minimal dispersion 1 month after injection (figs. S10 and S11). The 980-nm NIR pulses triggered membrane depolarization sufficient to generate photocurrents and evoke spikes in VTA DA neurons. The photocurrent amplitudes of ChR2 increased in response to elevated intensity of the incident NIR light under voltage clamp (Fig. 2,  C and D) . In the absence of UCNPs, no inward photocurrent was detected upon NIR irradiation (Fig. 2C) . The activation kinetics of ChR2 by NIR upconversion was slower than that of blue light-activated ChR2 ( fig. S6 ) (30) but comparable to that of recently reported red-shifted rhodopsins (10) . NIR irradiation could also evoke action potentials of DA neurons, as shown in current-clamp traces. Trains of NIR illumination at 10 to 50 Hz elicited multiple spikes (Fig. 2E) . The spike probability showed no significant dependence on the frequency of the NIR light (Fig. 2F) .
We next tested the in vivo utility of UCNPmediated NIR upconversion optogenetics. We sensitized VTA DA neurons of TH-Cre mice to transcranial NIR stimulation through viral delivery of ChR2 followed by bilateral UCNP injection (Fig. 3A) . Anesthetized mice were exposed to transcranial pulsed NIR irradiation (15- were mapped by imaging the expression of c-Fos (Fig. 3, B and C, and fig. S13 ). Neuronal excitation was only triggered by NIR light in ChR2-transfected mice in the presence of UCNPs, as indicated by the significantly higher proportion of c-Fos-positive cells in areas where UCNP injection and ChR2 expression overlapped. We injected UCNPs to just one side of the VTA and observed NIR-induced c-Fos expression only in the injected hemisphere ( fig. S14 ). We also observed up-regulation of c-Fos expression in the ventral striatum ( fig. S15 ), which receives inputs from VTA DA neurons (31), indicating NIR-evoked excitation of postsynaptic structures of the targeted neurons. Control mice with UCNP injection, ChR2 expression, or NIR stimulation alone showed no significant c-Fos expression in either VTA or ventral striatum. We evaluated the real-time efficacy of NIRevoked excitation of VTA DA neurons with fastscan cyclic voltammetry (FSCV) (Fig. 3D) . Striatal DA transients reflect the phasic spike activity of VTA DA neurons (31) and have therapeutic implications for the treatment of major depression. In nomifensine-pretreated mice with both UCNP injection and ChR2 expression in VTA, we detected DA release that was temporally locked to transcranial NIR stimulation (15-ms pulses at 20 Hz, 700-mW peak power) (Fig. 3F) . After a 2-s NIR stimulation, striatal DA release lasted for more than 15 s and peaked at~5 s after light onset (Fig. 3, F and G) . We detected no significant DA release in control mice with omission of NIR stimulation, UCNP injection, or ChR2 expression (Fig. 3, G to I) . We compared the efficacy of NIR with blue light in evoking DA release by VTA DA neurons (Fig. 3E) . The tip of an optic fiber transmitting NIR or blue light was positioned at various distances from the VTA target for optogenetic activation of DA neurons. When illuminating from a distance of 0.5 mm, NIR and blue light triggered similar amounts of DA release in ventral striatum (Fig.  3E and fig. S16 ). However, transcranial application of blue light did not result in striatal DA release (Fig. 3, E and I) . Furthermore, NIR stimulation showed significantly slower attenuation in DA release with the increase of the distance from fiber tip to VTA (Fig. 3E) .
We next expanded the application of in vivo upconversion optogenetics to multiple modes of neural control, including inhibition, as well as to different brain regions. First, we developed green-emitting UCNPs to match the maximum absorption of rhodopsins that hyperpolarize neurons, such as NpHR and Arch, to achieve noninvasive neuronal inhibition. The emission of UCNPs was tuned to~540 nm by codoping Er 3+ and Yb 3+ into the NaYF 4 host lattice (Fig. 4A and  fig. S1 ). We then assayed the ability of NaYF 4 :Yb/ Er@SiO 2 UCNPs to inhibit hippocampal activity during chemically induced hyperexcitability. Arch was virally expressed in excitatory neurons in the CA1 and dentate gyrus (DG) regions of the calcium-calmodulin-dependent kinase II (CamKII)-Cre mice, and green-emitting UCNPs were injected into the same region (Fig. 4B ). Mice were anesthetized and received the excitotoxin kainic acid (KA) at a dose used to induce seizure. We then applied transcranial low-intensity chronic pulsed NIR irradiation (3-ms pulses at 10 Hz, 120 min, 750-mW peak power, 22.5-mW average power) to inhibit neural activity in the hippocampus. Compared to all controls, mice with Arch expression, UCNP injection, and NIR stimulation showed a significant decrease in KA-induced c-Fos expression in the granule cells of the DG (Fig. 4 , C and D), indicating effective silencing of hippocampal neurons by UCNP-mediated Arch activation. When NIR irradiation or Arch delivery was only unilaterally applied, distinct levels of c-Fos expression were observed between the two hemispheres ( fig. S17 ). Next, we examined if UCNP-mediated optogenetics could be used for noninvasive synchronization of neural activity. We targeted our NIR stimulation to inhibitory neurons in the medial septum, a key node in the network generating the theta oscillation (32, 33) . In vivo recordings of hippocampal local field potential (LFP) were performed during transcranial NIR irradiation of anesthetized parvalbumin (PV)-Cre mice with ChR2 expression and UCNP injection targeted to the medial septum (Fig. 4, E and F) . Pulsed NIR stimulation in the theta frequency range (6 to 12 Hz) entrained the hippocampal theta oscillation in a frequency-dependent manner (Fig. 4, G and  H) . Control animals without ChR2 expression or UCNP injection showed no oscillation entrainment upon NIR irradiation (Fig. 4G) .
Finally, we used the UCNP-mediated optogenetics to alter behavior of an awake animal by targeting NIR excitation to granule cells in the hippocampus involved in memory recall. Recent studies have demonstrated the neuronal activitydependent tagging of memory-encoding hippocampal neurons by ChR2 and subsequent optogenetic reactivation of these engrams (34) . We injected blue-emitting UCNPs into the DG of c-fos-tTA (tetracycline transcriptional activator) transgenic mice and labeled active c-Fos-expressing DG granule cells with ChR2 during the encoding of fear memory in the absence of doxycycline (Dox) (Fig.  4, I to K, and fig. S18 ). We then applied transcranial NIR stimulation (15-ms pulses at 20 Hz, 250-mW peak power) to reactivate labeled granule cells. NIR irradiation increased freezing behavior of the mice during laser illumination in a safe context (Fig. 4L) . Animals with no UCNP injection or ChR2 expression showed no significant change in freezing when NIR irradiation was applied (Fig. 4, M to O) . Moreover, the behavioral effect of NIR stimulation in this experiment was observed 2 weeks after the injection of UCNPs, indicating their long-term in vivo utility. This timing is consistent with our findings that no extensive diffusion or degradation of UCNPs was observed 1 month after injection (figs. S10 and S11).
These findings demonstrate that UCNP-mediated optogenetics is a flexible and robust minimally invasive nanotechnology-assisted approach for optical control of in vitro and in vivo neuronal activity. We show spectral tuning of UCNPs for compatibility with the current toolbox of lightactivated channels (9) that is sufficient for functional activation and inhibition across a variety of deep brain structures. Future characterization of the interaction of UCNPs with neural tissue will allow for better biocompatibility and long-term utility. In parallel, systematic optimization of the dose of UCNP injection and the parameters of NIR stimulation will provide improved accuracy and safety. Such data might also present an upper limit to the adaptability and efficiency of NIR stimulation. Furthermore, refinements of the nanoparticles to establish precise cell-type or intracellular targeting (17, 18) , as well as improved delivery methods that would further reduce invasiveness (35) , will advance the utility of the approach. These methods, combined with the enhanced ability to express light-sensitive channels in the brain, may allow UCNP-mediated neuronal control to complement or extend current approaches to deep brain stimulation and neurological disorder therapies.
